These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30683443)

  • 21. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
    Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
    Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease.
    Kampouraki E; Kamali F
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):789-797. PubMed ID: 28635328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs).
    van Gorp RH; Schurgers LJ
    Nutrients; 2015 Nov; 7(11):9538-57. PubMed ID: 26593943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anticoagulation therapy and the use of non-vitamin K antagonist oral anticoagulants in the elderly].
    Öngen Z
    Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 5):86-88. PubMed ID: 28976390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011-2014.
    Schuh T; Reichardt B; Finsterer J; Stöllberger C
    J Thromb Thrombolysis; 2016 Oct; 42(3):447-51. PubMed ID: 27221106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of novel oral anticoagulants: a comparison to vitamin K antagonists.
    Katsianis A; Petrou E; Kostopoulou A; Theodorakis G
    Cardiovasc Hematol Agents Med Chem; 2014; 12(1):9-13. PubMed ID: 25470148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of bleeding complications due to oral anticoagulant drugs].
    Riess H
    Laryngorhinootologie; 2015 Oct; 94(10):697-709. PubMed ID: 26468622
    [No Abstract]   [Full Text] [Related]  

  • 32. Oral anticoagulant monitoring: Are we on the right track?
    Onundarson PT; Flygenring B
    Int J Lab Hematol; 2019 May; 41 Suppl 1():40-48. PubMed ID: 31069986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morbidity and mortality after fragility hip fracture surgery in patients receiving vitamin K antagonists and direct oral anticoagulants.
    Frenkel Rutenberg T; Velkes S; Vitenberg M; Leader A; Halavy Y; Raanani P; Yassin M; Spectre G
    Thromb Res; 2018 Jun; 166():106-112. PubMed ID: 29727737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
    Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracranial complications after minor head injury (MHI) in patients taking vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs).
    Riccardi A; Spinola B; Minuto P; Ghinatti M; Guiddo G; Malerba M; Lerza R
    Am J Emerg Med; 2017 Sep; 35(9):1317-1319. PubMed ID: 28400068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of bleeding in patients receiving direct oral anticoagulants.
    Hellenbart EL; Faulkenberg KD; Finks SW
    Vasc Health Risk Manag; 2017; 13():325-342. PubMed ID: 28860793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants.
    Riva N; Ageno W
    Semin Thromb Hemost; 2015 Mar; 41(2):178-87. PubMed ID: 25703519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Plitt A; Ruff CT; Giugliano RP
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1019-34. PubMed ID: 27637305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.